Cite
HARVARD Citation
Augustin, M. et al. (2022). Secukinumab demonstrated sustained retention, effectiveness and safety in a real‐world setting in patients with moderate‐to‐severe plaque psoriasis: long‐term results from an interim analysis of the SERENA study. Journal of the European Academy of Dermatology and Venereology. pp. 1796-1804. [Online].